Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated

Funding through borrowings associated with the introduction of MHB018A

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Borrowing to Fund the Upfront Fee under the MHB018A Licensing-In AgreementA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1First statedAnnual report

    「To finance the upfront payment under the agreement for the in-licensing of MHB018A, a treatment for thyroid eye disease, by its subsidiary あすか製薬株式会社, the company resolved at a Board of Directors meeting on 26 October 2026 to borrow funds and drew down the borrowing on 30 October 2026.」

    To pay the upfront payment for the in-licensing of MHB018A, the company borrowed ¥11,276 million from MUFG Bank on 30 October 2026 and also established and drew on a ¥4,300 million overdraft facility and ¥1,700 million in commitment lines with 5 companies.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Funding through borrowings associated with the introduction of MHB018A | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) | Komori